U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07861932) titled 'A Phase 1/2a Study of K-1728 in Advanced Solid Tumors' on Sept. 24.
Brief Summary: This first-in-human, open-label, multicenter study evaluates K-1728 administered as monotherapy and in combination in participants with advanced or metastatic solid tumors. The study assesses the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of K-1728.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Breast Neoplasms
Solid Tumors
PIK3CA Gene Mutation
Intervention:
DRUG: K-1728
K-1728 will be administered orally once daily in 28-day cycles
DRUG: Fulvestrant
Fulvestrant will be administered intramus...